Pharmaguy's Insights Into Drug Industry News
184.9K views | +17 today
Follow
Pharmaguy's Insights Into Drug Industry News
Pharmaguy curates and provides insights into selected drug industry news and issues.
Curated by Pharma Guy
Your new post is loading...
Your new post is loading...
Scooped by Pharma Guy
Scoop.it!

Shire to Defend Its Binge Eating Disorder Screener at 2016 APA Annual Meeting

Shire to Defend Its Binge Eating Disorder Screener at 2016 APA Annual Meeting | Pharmaguy's Insights Into Drug Industry News | Scoop.it

Shire will present new research on Binge Eating Disorder (B.E.D.) and Attention-Deficit/Hyperactivity Disorder (ADHD) at the upcoming 169th Annual Meeting of the American Psychiatric Association (APA) in Atlanta, GA, demonstrating its ongoing commitment to furthering the understanding and management of psychiatric disorders.

 

“The data being presented this year at APA will address several important topics within the adult psychiatry therapeutic area, including the characterization of eating behaviors in adults with binge eating disorder, as well as patterns of prescription medication use in two psychiatric disorders,” said Barry K. Herman, MD, MMM, DLFAPA, Global Medical Team Lead, Senior Medical Director for Shire. “These presentations underscore our long-standing commitment to furthering knowledge of psychiatric conditions and advancing research into the unmet needs of people with B.E.D. and ADHD.”

 

Posters presented during the conference will include:

 

Poster Number P6-048; Monday, May 16, 2:00pm EDT: The Use and Value of the 7-Item Binge Eating Disorder Screener in Clinical Practice; Presented by Barry K. Herman, MD, MMM, DLFAPA

 

“Continued research on binge eating disorder in adults is crucial to expanding our understanding of the disorder,” said Cynthia Bulik, PhD, FAED, Distinguished Professor of Eating Disorders, Department of Psychiatry, University of North Carolina at Chapel Hill, and co-author of P6-136. “We value our collaboration with Shire to enhance efforts to educate health care professionals who evaluate adults living with B.E.D.”

Pharma Guy's insight:

Shire makes it easy for anyone to convince their docs to prescribe Vyvanse for their B.E.D. (Binge Eating Disorder), which I described in Pharma Marketing Blog: "How Virtually Anyone Can Get an Rx for Amphetamine... Sorry, I Meant to Say Vyvanse"

 

Shire's B.E.D. symptom checklist, IMHO, is a perfect aid for people who wish to abuse a dangerous Schedule II controlled stimulant.

 

According to my more or less truthful answers to the screener, I may suffer from B.E.D. and be able to convince my doc to prescribe me Vyvanse. 

 

I suggested (http://bit.ly/BEDchecklist) that Shire remove this tool from its website to prevent possible abuse of this medication, but now I see Shire wants to "prove" to the medical community that this bogus test has value in clinical practice!

 

"The strategy for a new drug to treat binge-eating disorder reveals how a pharmaceutical company can influence the treatment of a medical condition," said Dr. Lawrence H. Diller, a behavioral pediatrician in Walnut Creek, Calif. Read: "Shire Makes It Easy for the Public to Learn About the ‘Glories of Amphetamine’"; http://sco.lt/7xiqtl 

more...
No comment yet.
Scooped by Pharma Guy
Scoop.it!

Shire Makes It Easy for the Public to Learn About the "Glories of Amphetamine"

Shire Makes It Easy for the Public to Learn About the "Glories of Amphetamine" | Pharmaguy's Insights Into Drug Industry News | Scoop.it
The strategy for a new drug to treat binge-eating disorder reveals how a pharmaceutical company can influence the treatment of a medical condition.


With the approval of Vyvanse for binge eating, “now we have another reason for the public to learn about the glories of amphetamine — it’s very worrisome,” said Dr. Lawrence H. Diller, a behavioral pediatrician in Walnut Creek, Calif., who has written about A.D.H.D. drugs. “My hat’s off to Shire. They’ve done it again.”


[The image shows a 1954 advertisement for an methamphetamine-based appetite control drug called Opidice. Shire's new drug Vyvanse also uses a type of amphetamine.]


Dr. Diller and others said Shire appeared to be following a familiar drug industry playbook by promoting awareness of a disorder, in this case binge eating, before more directly marketing its treatment. A company website, BingeEatingDisorder.com, makes no mention of Vyvanse but provides detailed information about how to talk about the disorder with a doctor, including a printable symptom checklist and sample opening lines to start the conversation. The site also tells patients “don’t give up” if a doctor initially resists.


Pharma Guy's insight:


Shire also makes it easy for anyone to convince their docs to prescribe Vyvanse for their B.E.D. (Binge Eating Disorder), which I described in Pharma Marketing Blog 3 weeks ago: "How Virtually Anyone Can Get an Rx for Amphetamine... Sorry, I Meant to Say Vyvanse"


BTW, this story illustrates how major news sources like the NYT and WSJ follow the lead of bloggers like me rather than vice versa. I wrote about this on Feb 5. The NYT writes about it on Feb 24 and the WSJ (Pharmalot) writes about what the NYT wrote on Feb 25. Argggh!

more...
No comment yet.